The Insulin Receptor pipeline drugs market research report outlays comprehensive information on the Insulin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Insulin Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Oncology, Ophthalmology, and Central Nervous System which include the indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Solid Tumor, Breast Cancer, Graves’ Ophthalmopathy, Retinal Vein Occlusion, Alzheimer’s Disease, and Parkinson’s Disease. It also reviews key players involved in Insulin Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Insulin Receptor pipeline targets constitutes close to 190 molecules. Out of which, approximately 169 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 14, 2, 28, 21, 23, 9, 51, and 8 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical, and Discovery comprises 1, 1, 16, and 3 molecule.
Insulin Receptor overview
The insulin receptor (IR) is a transmembrane receptor that plays a key role in regulating glucose homeostasis and cell growth and differentiation. It is a heterotetrameric glycoprotein composed of two extracellular α-subunits and two transmembrane β-subunits. The α-subunits bind insulin, while the β-subunits have intrinsic tyrosine kinase activity. Upon insulin binding, the IR undergoes autophosphorylation of its tyrosine residues and activates a cascade of intracellular signaling pathways. These pathways ultimately lead to the uptake of glucose into cells, the suppression of glucose production by the liver, and the stimulation of protein and glycogen synthesis.
For a complete picture of Insulin Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
